Key result
Target-specific oral anticoagulants are effective alternatives to warfarin for reducing the risk of thromboembolism in patients with nonvalvular atrial fibrillation, offering modestly favorable bleeding risk profiles.
Why the study?
How should antithrombotic therapy be selected for patients with atrial fibrillation based on the 2014 AHA/ACC/HRS guidelines?
How should antithrombotic therapy be selected for patients with atrial fibrillation based on the 2014 AHA/ACC/HRS guidelines?
This review provides a clinical decision-making rationale for selecting antithrombotic therapy in atrial fibrillation based on the 2014 AHA/ACC/HRS guidelines.
May guide antithrombotic selection in AF per 2014 guidelines; leaves open need for updated evidence in contemporary practice.
When considering anticoagulant therapy for patients with atrial fibrillation, one must balance the reduction in risk of thromboembolism that this therapy offers against the risk of bleeding that it poses. The American Heart Association, American College of Cardiology, and Heart Rhythm Society updated their atrial fibrillation guidelines in 2014. This review outlines a rationale for clinical decision-making based on the new guidelines and summarizes the currently approved drugs.
No takes yet. Share an insight, caveat, or question.
Tanaka‐Esposito et al. (2014) conducted a review in Atrial fibrillation. Antithrombotic therapy (warfarin and target-specific oral anticoagulants) was evaluated. Target-specific oral anticoagulants are effective alternatives to warfarin for reducing the risk of thromboembolism in patients with nonvalvular atrial fibrillation, offering modestly favorable bleeding risk profiles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: